Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19366287 | 0.89 | SMN1; SMN2 (0.37) | MAOASMN1; SMN2KDM4EBRD4MEN1 | |
| SCHEMBL17538348 | 0.89 | MAOA (0.36) | MAOASMN1; SMN2MAPTHTTKDM4E | |
| SCHEMBL17531505 | 0.88 | SLC18A2 (0.32) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL17531504 | 0.78 | SLC18A2 (0.34) | SMN1; SMN2KDM4EMEN1KMT2ANQO2 | |
| SCHEMBL17538347 | 0.77 | SMN1; SMN2 (0.40) | MAOASMN1; SMN2KDM4ETSHRBRD4 | |
| SCHEMBL19366291 | 0.77 | MEN1 (0.33) | SMN1; SMN2MAPTHTTKDM4EMEN1 | |
| SCHEMBL17531485 | 0.73 | CYP19A1 (0.34) | — | |
| SCHEMBL17538307 | 0.70 | ACHE (0.36) | SMN1; SMN2MAPTHTTMEN1KMT2A | |
| SCHEMBL19067933 | 0.69 | SLC18A2 (0.34) | — | |
| SCHEMBL17538357 | 0.69 | CYP19A1 (0.49) | MAOASMN1; SMN2TSHRBRD4CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170266181-A1 | NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266181-A1 | NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY | AR, NR5A1, BRCA1 | MAOA 3899/4885SMN1; SMN2 106/4885MAPT 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.